ORIGINAL ARTICLE. Corticosteroids vs Corticosteroids Plus Antiviral Agents in the Treatment of Bell Palsy
|
|
- Rose Meryl Marsh
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE vs Plus Antiviral Agents in the Treatment of Bell Palsy A Systematic Review and Meta-analysis John K. Goudakos, MD, MSc; Konstantinos D. Markou, MD, PhD Objective: To review systematically and meta-analyze the results of all randomized controlled trials (RCTs) for the treatment of patients with Bell palsy with corticosteroids vs corticosteroids plus antiviral agents. Data s: A MEDLINE, EMBASE, Cochrane Library, and CENTRAL database search, followed by extensive hand-searching for the identification of relevant studies. No time and language limitations were applied. Study Selection: Prospective RCTs on the treatment of patients with Bell palsy. Data Extraction: Odds ratios (ORs), 95% confidence intervals (CIs), and tests for heterogeneity were reported. Data Synthesis: Five studies were eventually identified and systematically reviewed. Meta-analysis was performed for 4 studies. Regarding the complete recovery rate of facial nerve paralysis 3 months after initiation of therapy, the current systematic review and metaanalysis suggests that the addition of an antiviral agent does not provide any benefit (OR, 1.03 [95% CI, ]; P=.88). The same conclusion emerged at posterior (fourth, sixth, and ninth) months of assessment. Subgroup analysis, conducted on the basis of time point of therapy initiation, type of antiviral agent, and blindness of assessments did not change the results obtained. The occurrence rate of adverse effects attributable to therapy choice was not significantly different between patients receiving corticosteroids and those following combined treatment. Conclusion: The present systematic review and metaanalysis, based on the currently available evidence, suggests that the addition of an antiviral agent to corticosteroids for the treatment of Bell palsy is not associated with an increase in the complete recovery rate of the facial motor function. Arch Otolaryngol Head Neck Surg. 2009;135(6): Author Affiliations: First Department of Otorhinolaryngology Head and Neck Surgery, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. BELL PALSY, OR IDIOPATHIC FAcial paralysis, is the most common cause of acute facial paralysis, with an annual incidence reported to range from 20 to 45 cases per persons. 1,2 The main clinical symptom of Bell palsy is facial motor dysfunction, the degree of which varies from minor weakness to complete paralysis depending on the amount of neural injury. Genetic factors, vascular ischemia, and inflammation owing to viral infection or autoimmune disorders have been proposed as the possible underlying cause, but the etiology remains unknown. 3-5 The theory of viral etiology was first proposed by McCormick, 6 who suggested the acute inflammatory neuropathy of the seventh cranial nerve, owing to the presence of herpes simplex virus (HSV) in the geniculate ganglion. 7 In 1996, Murakami et al 8 isolated the HSV genome from the facial nerve endoneurial fluid of patients with Bell palsy, additionally supporting the viral etiology of the disease. Considering the natural history of the disease, Peitersen, 2 in a retrospective study of 2500 cases of Bell palsy, reported that 70% of the patients presented with complete paralysis of the facial nerve at initial examination, with only 61% of them achieving ultimate recovery. The same study 2 also reported that partial regain of facial tone or movement was established in 85% of all patients within 3 weeks, and full recovery was typically achieved within 2 months. Nowadays, the treatment of choice for Bell palsy has not yet been established. The therapeutic drug choices for the treatment of the idiopathic facial paralysis are (1) corticosteroids, (2) antiviral therapy (acyclovir sodium or valacyclovir hydrochloride), and (3) a combination of corticosteroids with an antiviral agent (combined therapy). 558
2 are considered to be the most widely accepted treatment for Bell palsy. The rationale for early treatment with the use of corticosteroids for patients with Bell palsy is based on the reports of facial nerve swelling during decompression operations. 9,10 Several nonrandomized controlled trials (non-rcts) have advocated the use of corticosteroids in facial palsy as the treatment of choice. In 2000, a meta-analysis by Ramsey et al 11 suggested the significant improvement in recovery from facial paralysis in patients with Bell palsy who received corticosteroids. However, a recently published systematic review and meta-analysis 12 indicated that, at present, the beneficial role of corticosteroids in Bell palsy treatment remains in doubt. The possible association between Bell palsy and viral infection led to the use of an antiviral agent in the therapeutic plan of the disease, either as monotherapy or in combination with corticosteroids. Based on the results of a current systematic review and meta-analysis, insufficient evidence exists to make definitive recommendations regarding the effect of antiviral agents on Bell palsy. 13 Recent multicenter controlled trials 14,15 have evaluated the combined treatment strategy (corticosteroids plus antiviral agents) vs corticosteroids alone in the therapy of Bell palsy. Conflicting results about the benefit of adding antiviral agents for the recovery of facial nerve paralysis have been presented. The purpose of the present systematic review and metaanalysis is to address the following question: Among patients with Bell palsy, is the full recovery of facial paralysis significantly different between patients who receive corticosteroids and those who receive combined treatment with corticosteroids and an antiviral agent? METHODS SEARCH STRATEGY We performed a computer literature search in MEDLINE, EMBASE, the Cochrane Library, 16 and CENTRAL electronic databases from January 10 to February 10, 2008, to identify studies that answered the question of interest. For this purpose, we used the following free-text terms: Bell palsy or idiopathic facial nerve paralysis or facial palsy combined with drug therapy or steroids/corticosteroids/cortisone/prednisolone/ presolone/methylprednisolone/dexamethasone/glucorticoids or antiviral/acyclovir/valacyclovir or treatment or therapy and limited to human. In addition, extensive handsearching of the references of all relevant studies was also performed. No time and language limitations were applied. SELECTION OF STUDIES All criteria for inclusion or exclusion of studies in the present systematic review were specified prior to the literature search. For a study to be eligible, the following criteria had to be met: (1) the study had to be an RCT, comparing any type of corticosteroid therapy with combined treatment of corticosteroids with any type of antiviral agent, regardless of the route (oral or parenteral), the dose, and the duration of administration of the therapies; (2) the study had to include patients with unilateral facial nerve weakness of no identifiable cause seen within 7 days of the onset of weakness; (3) the follow-up protocol had 262 Potentially relevant studies identified and screened for retrieval 39 Studies retrieved for more detailed evaluation 12 Potentially appropriate studies to be included in the systematic review 5 Studies included in the systematic review Figure 1. Flow diagram for study selection. 223 Studies excluded after screening the title 27 Studies excluded after screening the abstract 7 Studies excluded from the systematic review, according to inclusion criteria to include assessments of patients clinical status at least 3 months after the initial onset of the disease and start of therapy; and (4) the study had to include patients who started therapy within 7 days from the onset of the disease. The following exclusion criteria were established: (1) any studies that included patients with uncontrolled diabetes mellitus, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, or systematic infection and (2) any study that included pregnant or breastfeeding women were excluded. In case the studies did not offer all the necessary information for the assessment of potential eligibility, the authors of those studies were contacted and asked to provide the missing data. STUDIES IDENTIFIED The electronic search resulted in the identification of 262 publications. Of these, 39 were found to be potentially eligible publications. The abstracts of these studies were examined, and 12 articles that could provide data to answer the research question of interest were identified (Figure 1). The full text of these studies was examined thoroughly, resulting in the exclusion of 7 publications. Specifically, these studies were excluded because (1) they did not match with the research question of interest (n=4), (2) the follow-up was less than 3 months (n=2), or (3) their data overlapped those of other publications (n=1); the study with the more extensive sample size was considered eligible in the present systematic review. As a consequence, 5 studies 14,15,17-19 comparing corticosteroids with the combined therapy of corticosteroids plus antiviral agents in patients with Bell palsy were finally identified (Table 1). Each of us independently assessed eligibility of these studies for the present systematic review. Any disagreement was resolved unanimously by discussion. DATA EXTRACTION Both of us performed data extraction, and the following data were recorded from each of the eligible studies: general characteristics (type of study, citation data, number of patients included, and their baseline characteristics), procedural data (type of randomization, inclusion criteria, protocol of follow-up, protocol of corticosteroid therapy or combined treatment and the number of patients who dropped out of the study), and outcome data (facial nerve recovery based on specific grading scale, adverse effects of each therapy strategy). To perform the intention-to-treat analysis, all patients who were initially allocated to each treatment group were analyzed together, regardless of whether they completed or received that treatment. 559
3 Table 1. Demographic Data of the 5 Studies Included in the Systematic Review No. Sample Size of Sample Size of Combined Therapy a Sample Size Randomization Sullivan et al, Automated (telephone) Patient Allocation Contact With Authors Permuted-block technique Yes, data not provided Hato et al, Random numbers Sealed envelope Yes, data provided Adour et al, NA NA Yes, data not provided Inanli et al, NA NA Yes, data not provided Melo et al, NA NA Yes, data provided Abbreviation: NA, not analyzed. a Combined therapy: corticosteroids plus antiviral agents. OUTCOME MEASURES The main outcome measure chosen for the systematic review and meta-analysis was the complete recovery of facial motor function 3 months after the initiation of therapy. Assessments of facial motor function at posterior months (at 4, 6, and 9 months) after the therapy started were also conducted. Many facial grading systems have been introduced for the assessment of motor function of facial nerve. In the present systematic review, the House and Brackmann 20 facial nerve grading system, which has been adopted as a standard by the Facial Nerve Disorders Committee of the American Academy of Otolaryngology Head and Neck Surgery, was chosen for the assessment of the primary outcome. Conversion of scores of other grading systems to the scales of the House-Brackmann system was performed, owing to its universal acceptance for calculation of dysfunction of facial nerve disorders. Secondary outcome measures included the occurrence rate of adverse effects in each study group attributable to treatment strategies (corticosteroids and corticosteroids plus antiviral drugs). These adverse effects included dizziness, dyspepsia, nausea, constipation, hunger, vomiting, insomnia, night sweats, and other symptoms attributable to drug choice. QUANTITATIVE DATA SYNTHESIS The dichotomous data results for each of the eligible studies for meta-analysis were expressed as an odds ratio (OR) with 95% confidence intervals (CIs). These results were combined for meta-analysis by applying the Mantel-Haenszel model 21 when using the fixed-effects method, and the DerSimonian and Laird model 22 when using the random-effects method. Revman software (version 4.2 for Windows; Nordic Cochran Centre, the Cochrane Collaboration, Copenhagen, Denmark) was used to combine the results for meta-analysis. Inconsistency of studies (study-to-study variation) was assessed by using the 2 statistic (the hypothesis tested was that the studies were all drawn from the same population, ie, from a population with the same effect size). A fixed-effects model was used in which no heterogeneity was present. In the presence of significant heterogeneity (P.05), a random-effects model was applied. Subgroup analyses were performed depending on (1) the duration between disease onset and the start of therapy (early treatment was considered to be the therapy starting within 3 days of the disease onset), (2) the type and dosage of the corticosteroid and antiviral agent used in each study group, and (3) studies in which physicians who performed assessments of the outcomes were actually aware of allocated treatment. Sensitivity analyses were performed to check the stability of the results obtained by excluding (1) studies that did not report the procedure of randomization and patient allocation clearly and (2) studies that did not provide detailed data regarding the diagnostic criteria of Bell palsy. RESULTS Five studies 14,15,17-19 fulfilled the inclusion criteria. Characteristics of the eligible studies are listed in Table 1 and Table 2. SYSTEMATIC REVIEW The eligible studies 14,15,17-19 were published from 1996 to All studies were RCTs in design, and their sample sizes ranged from 29 to 272 patients. A total of 738 patients were reviewed (corticosteroids group, n=372; combined therapy group, n=366) (Table 1). Regarding the type of corticosteroid, patients in 4 studies received prednisolone, whereas in 1 study deflazacort was used. In the combined therapy group, the regimen included the corticosteroid plus an antiviral agent, acyclovir or valacyclovir. In all studies the drugs were administered orally. Details about the daily dose and the length of regimen of each study group are presented in Table 2. In all studies, the procedure of follow-up included assessments of the patients for at least 3 months. The number of patients who were lost during the follow-up period (dropouts) in each study group was reported in 4 of 5 eligible studies. 14,15,17,18 All trials used the full recovery of facial nerve motor function as the main outcome measure. Patients in 4 trials 14,15,17,19 commenced therapy within 3 days of onset of the disease. The initial severity of the facial nerve dysfunction was reported in 3 studies 14,15,17 (Table 2). The House-Brackmann grading system was used in 3 studies 15,18,19 for scoring the facial nerve paralysis and its recovery. The Yanagihara grading system and Facial Paralysis Recovery Profile (FPRP) were used in the remaining 2 studies, 14,17 and in these 2 studies, the authors reported the conversion of the used grading system (Yanagihara or FPRP) to the scores of House-Brackmann 560
4 Table 2. Characteristics of the 5 Studies Included in the Systematic Review Sullivan et al, Hato et al, Adour et al, Inanli et al, Melo et al, / Age, Mean (SD), y Sex, % Male Severity of Palsy, Mean (SD) Therapy Start a 42.7 (15.9)/43.7 (16.4) 55.9/ (1.2) 3.4 (1.2) Within 3d 52.3/ / /14.7 Within 7d c 42.6 (15.1)/41.9 (14.1) 43/55 3.1/3.0 Within 3d 42/38 59/70 NR Within 3d 25 mg twice a day for 20 mg, 3 times a day for 1-5 days; 10 mg, 3 times a day for 6-8 days; 10 mg, once per day for 9-1 mg/kg for 5 days tapered to 10 mg/d for remaining 5 days 1 mg/kg for 12 days 30 d 45 d NR NR Deflazacort, 60 mg/d for 2 days, reducing doses for 7 days Drug and Dosage b Steroid plus acyclovir, 400 mg, 5 times a day for Steroid plus valacyclovir, 500 mg, twice a day for 5 days Steroid plus acyclovir, 2000 mg/d for Steroid plus acyclovir, 2400 mg/d for Steroid plus valacyclovir, 1500 mg, once a day for 1-7 days Duration of Follow-up, mo Dropouts, No NR 6 7 Abbreviation: NR, not reported. a Time after disease onset that therapy initiated. b Combined therapy: corticosteroids plus antiviral agents. c Outcome findings for patients who were recruited within 3 days of disease onset were provided. d Distribution to each study group was not provided. Adour et al, Inanli et al, Sullivan et al, Hato et al, Weight, % OR (95% CI) Nonevent, M-H, Fixed 1.49 ( ) 0.57 ( ) 0.85 ( ) 1.09 ( ) Total ( ) Heterogeneity: χ 2 3 = 1.59 (P =.66); I 2 = 0% Test for overall effect: z = 0.15 (P =.88) OR (95% CI) Nonevent, M-H, Fixed Figure 2. Odds ratio (OR) of complete recovery rate of facial motor function 3 months after the initiation of therapy. CI indicates confidence interval; M-H, Mantel-Haenszel. 21 Combined therapy group indicates corticosteroids plus antiviral agents. system. In 2 studies, 15,17 clinicians assessing the recovery profile of the patients were blinded to allocated treatment. Three studies 15,18,19 reported that there is no evidence that antiviral agents provide additional recovery benefit for patients with Bell palsy. In contrast, the 2 remaining studies 14,17 reported that therapy with corticosteroids plus antiviral agents is superior to corticosteroids alone, regarding the complete recovery of facial motor function of patients with idiopathic acute facial paralysis. Three studies 14,15,17 provided data about the adverse effects that occurred in each study group, which could be attributed to treatment strategies. META-ANALYSIS Four 14,15,17,19 of 5 eligible studies provided relevant data for quantitative synthesis. The complete recovery rate of facial motor function at 3 months after the initiation of therapy was not significantly different between the corticosteroids group and the combined therapy group (OR, 1.03 [95% CI, ]; P=.88; heterogeneity, P=.66; fixed-effects model) (Figure 2). Regarding assessment at 4, 6, and 9 months after initiation of therapy, meta-analysis was not feasible because results from only 1 study were available at each time 561
5 Hato et al, Sullivan et al, Weight, % OR (95% CI) Nonevent, M-H, Fixed 0.92 ( ) 1.17 ( ) Total ( ) Heterogeneity: χ 2 1 = 0.42 (P =.52); I 2 = 0% Test for overall effect: z = 0.11 (P =.91) OR (95% CI) Nonevent, M-H, Fixed Figure 3. Odds ratio (OR) of complete recovery rate of facial motor function at 3 months after the initiation of therapy, excluding studies that did not report detailed analysis of randomization procedure and patient allocation. CI indicates confidence interval; M-H, Mantel-Haenszel. 21 Combined therapy group indicates corticosteroids plus antiviral agents. Adour et al, Inanli et al, Sullivan et al, Hato et al, Weight, % OR (95% CI) Nonevent, M-H, Fixed 0.67 ( ) 1.76 ( ) 1.17 ( ) 0.67 ( ) Total ( ) Heterogeneity: χ 2 3 = 2.18 (P =.54); I 2 = 0% Test for overall effect: z = 0.30 (P =.77) OR (95% CI) Nonevent, M-H, Fixed Figure 4. Odds ratio (OR) of complete recovery rate of facial motor function at 3 months after the initiation of therapy, including studies in which patients started treatment within 3 days of the onset of Bell palsy. CI indicates confidence interval; M-H, Mantel-Haenszel. 21 Combined therapy group indicates corticosteroids plus antiviral agents. point. It should be noted, though, that in the individual studies the observed recovery rate of facial motor function was not considerably different between the corticosteroids group and combined therapy group 4 (OR, 0.48 [95% CI, ]; P=.17), 6 (OR, 0.76 [95% CI, ]; P=.29), and 9 months after the initiation of therapy (OR, 1.53 [95% CI, ]; P=.25). Sensitivity analysis including only the studies that reported a detailed analysis of randomization procedure and patient allocation suggested that the recovery rate of facial motor function did not differ significantly between the corticosteroids group and combined therapy group (OR, 1.02 [95% CI, ]; P=.91; heterogeneity, P=.52; fixed-effects model) (Figure 3). Finally, these results did not change substantially by excluding the studies not clearly reporting the diagnostic criteria of Bell palsy (OR, 1.02 [95% CI, ]; P=.91; heterogeneity, P=.52; fixed-effects model). Subgroup analysis including only results of studies in which initiation of treatment was performed within 3 days of disease onset did not lead to a significant difference of complete recovery between the study groups (OR, 0.94 [95% CI, ]; P=.77; heterogeneity, P=.54; fixedeffects model) (Figure 4). In the study by Hato et al, 14 treatment started within 7 days of disease onset, and for this subgroup analysis the results of patients recruited within 3 days were used. In a further subgroup analysis, in which studies administering the same type of antiviral agent (acyclovir or valacyclovir) were analyzed, the rate of patients with complete recovery of facial motor function did not differ significantly (P.05) between the 2 treatment groups (corticosteroids and corticosteroids plus antiviral agent). Finally, subgroup analysis, based on the type of corticosteroid administrated, could not be performed because all the studies that were included in meta-analysis used the same type of steroid (prednisolone) in similar parenteral dosage. It should be noted that the recovery rate of facial motor function between the corticosteroid group and combined therapy group was not considerably different, excluding studies in which physicians performing the assessments of the outcome were aware of treatment allocation (OR, 0.99 [95% CI, ]; P=.97; heterogeneity, P=.28; fixedeffects model). The occurrence rate of adverse effects attributable to therapy choice did not differ significantly between the study groups (OR, 0.89 [95% CI, ]; P=.70; heterogeneity, P=.78; fixed-effects model). COMMENT Treatment decisions regarding patients with Bell palsy are doubtful and remain a common problem in medical practice. have been established as the therapy of choice, despite the fact that the available evidence from RCTs does not exhibit a clear benefit. However, the largest available RCT published recently suggested a benefit from the use of corticosteroids in patients with idiopathic acute facial paralysis. 15 The role of anti- 562
6 viral agents has been revealed since the establishment of the virus involvement in the etiology of Bell palsy. The natural course of Bell palsy, based on analysis of history of numerous cases, indicates that most patients recover within 3 months after the onset of the disease. 2 Regarding the complete recovery rate of the facial nerve paralysis 3 months after the disease occurrence, the current systematic review and meta-analysis suggests that the addition of an antiviral agent does not provide any benefit. This conclusion seems to be in agreement with the results of a recent report 23 dealing with the virologic background of Bell palsy, which indicates that, at first examination, reactivation of the HSV was detected in only 8% of patients. The lack of recovery advantage in patients receiving antiviral agents remained invariable at the 4-, 6-, and 9-month assessments after the therapy initiation. According to supporters of virus involvement in the etiopathogenesis of Bell palsy, except in the case of HSV, the reactivation of varicella zoster virus (VZV) is involved in the pathophysiologic course of a considerable proportion of patients. Valacyclovir, a prodrug of acyclovir, has been proposed as the antiviral agent that can improve the recovery rate of facial paralysis owing to its high bioavailability, which implies a much higher antiviral activity. However, in the present study, a subgroup analysis, based on the type of antiviral agent (acyclovir or valacyclovir), did not detect a benefit in the recovery of facial paralysis by adding either of the 2 agents. The rationale for early (within 3 days of onset of disease) treatment with corticosteroids in patients with Bell palsy was based on its theoretical effect on early occurring cytotoxic edema, being proposed as a prevention strategy to neural degeneration of facial nerves and as a therapy method for complete recovery of facial paralysis. 24,25 However, the results of the present metaanalysis do not confirm this assumption because the subgroup analysis on the basis of the timing of therapy initiation (within or not within 3 days of disease onset) supports the conclusion that early treatment does not provide any recovery advantage in patients with Bell palsy. The lack of benefit from the addition of antiviral agents to the therapeutic plan of patients with Bell palsy was also confirmed in the sensitivity analysis by excluding the studies that did not clearly report the diagnostic criteria of disease or the procedure of randomization and patient allocation. The accurate diagnosis of the acute idiopathic facial nerve paralysis depends on the exclusion of other causes that have similar symptoms. Particularly, zoster sine herpete, which can mimic the signs and symptoms of Bell palsy, which is caused by VZV, has an incidence rate ranging from 29% to 34% among patients with Bell palsy. 26,27 Consequently, data are needed regarding the virologic backgrounds of all participating patients and obtained by means of serologic and polymerase chain reaction examinations. In the present systematic review, only 1 study 14 excluded patients with VZV reactivation. The results of the present systematic review are liable to certain limitations. In 2 studies, 15,17 the investigators who were administering the treatment and assessing the outcome were not aware of study-group assignments. Moreover, because facial functional outcome assessments are semisubjective, a level of bias in the final outcome assessment scores should be considered in all trials. Revealing the statistical significance of treatment benefit in studies of Bell palsy requires a large number of patients owing to the variable and spontaneous recovery profile of patients. 2 In the present systematic review, time-to-event analysis was not incorporated in any of the eligible studies. Time-to-event analysis and estimation of the relative risk are considered to be the most appropriate methods for comparison of the recovery of facial nerve motor function between the 2 groups so that the time interval between the intervention and the event (recovery of facial nerve) will not be disguised. None of the eligible studies in the present systematic review reported their results on the basis of the intention-to-treat analysis. The rationale of the specific analysis is to provide the pragmatic estimate of the benefit of a change to treatment policy rather than an estimate of potential benefit to patients receiving treatment exactly as planned. 28,29 The results of the eligible studies in the present review were included in the quantitative data synthesis after their calculation on the basis of intention-to-treat analysis. CONCLUSIONS The current systematic review and meta-analysis suggests that addition of an antiviral agent to corticosteroids for the treatment of patients with Bell palsy is not associated with an increase in the complete recovery rate of facial motor function. Additional well-designed RCTs are needed to assess the potential value of antiviral addition to the recovery of facial palsy with more confidence. However, based on the currently available evidence, the addition of an antiviral agent to corticosteroids for the treatment of patients with Bell palsy is not justified. Submitted for Publication: June 4, 2008; final revision received November 3, 2008; accepted November 16, Correspondence: John K. Goudakos, MD, MSc, First Department of Otolaryngology Head and Neck Surgery, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece (jgoudakos@gmail.com). Author Contributions: Both authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Goudakos. Acquisition of data: Goudakos. Analysis and interpretation of data: Goudakos and Markou. Drafting of the manuscript: Goudakos. Critical revision of the manuscript for important intellectual content: Goudakos and Markou. Statistical analysis: Goudakos. Obtained funding: Goudakos. Administrative, technical, and material support: Goudakos and Markou. Study supervision: Goudakos and Markou. Financial Disclosure: None reported. Additional Contributions: K. K. Adour, M. L. Antunes, N. Hato, S. Inanli, and F. M. Sullivan contributed to this study. 563
7 REFERENCES 1. Campbell KE, Brundage JF. Effects of climate, latitude, and season on the incidence of Bell s palsy in the US Armed Forces, October 1997 to September Am J Epidemiol. 2002;156(1): Peitersen E. Bell s palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl. 2002;(549): Adour KK. Current concepts in neurology: diagnosis and management of facial paralysis. N Engl J Med. 1982;307(6): Burgess LP, Yim DW, Lepore ML. Bell s palsy: the steroid controversy revisited. Laryngoscope. 1984;94(11, pt 1): Lorber B. Are all diseases infectious? Ann Intern Med. 1996;125(10): McCormick DP. Herpes-simplex virus as a cause of Bell s palsy. Lancet. 1972;1 (7757): Takasu T, Furuta Y, Sato KC, Fukuda S, Inuyama Y, Nagashima K. Detection of latent herpes simplex virus DNA and RNA in human geniculate ganglia by the polymerase chain reaction. Acta Otolaryngol. 1992;112(6): Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med. 1996;124(1, pt 1): Cawthorne T. The pathology and surgical treatment of Bell s palsy. J Laryngol Otol. 1951;65(11): Fowler EP Jr. Medical and surgical treatment of Bell s palsy. Laryngoscope. 1958; 68(9): Ramsey MJ, DerSimonian R, Holtel MR, Burgess LP. Corticosteroid treatment for idiopathic facial nerve paralysis: a meta-analysis. Laryngoscope. 2000; 110(3, pt 1): Salinas RA, Alvarez G, Ferreira J. for Bell s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2004;(4):CD Allen D, Dunn L. Aciclovir or valaciclovir for Bell s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2004;(3):CD Hato N, Yamada H, Kohno H, et al. Valacyclovir and prednisolone treatment for Bell s palsy: a multicenter, randomized, placebo-controlled study. Otol Neurotol. 2007;28(3): Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell s palsy. N Engl J Med. 2007;357(16): Cochrane Library. Issue 1, www3.interscience.wiley.com/cgi-bin/mrwhome / /HOME. Accessed February 1, Adour KK, Ruboyianes JM, Von Doersten PG, et al. Bell s palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Ann Otol Rhinol Laryngol. 1996;105(5): Melo E, Antunes M, Ferreira PL. Quality of life in patients undergoing coronary revascularization. Rev Port Cardiol. 2000;19(9): Inanli S, Tutkun A, Ozturk O, et al. Idiopathic facial nerve paralysis treatment with acyclovir and prednisolone alone. Turkish Arch Otol. 2001;39: House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985;93(2): Mantel N, Haenszel WH. Statistical aspects of the analysis of data from retrospective studies of diseases. J Natl Cancer Inst. 1959;22(4): DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): Kawaguchi K, Inamura H, Abe Y, et al. Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell s palsy. Laryngoscope. 2007; 117(1): Lagalla G, Logullo F, Di Bella P, Provinciali L, Ceravolo MG. Influence of early high-dose steroid treatment on Bell s palsy evolution. Neurol Sci. 2002;23(3): De Diego JI, Prim MP, De Sarria MJ, Madero R, Gavilán J. Idiopathic facial paralysis: a randomized, prospective, and controlled study using single-dose prednisone versus acyclovir three times daily. Laryngoscope. 1998;108(4, pt 1): Grosheva M, Guntinas-Lichius O. Significance of electromyography to predict and evaluate facial function outcome after acute peripheral facial palsy. Eur Arch Otorhinolaryngol. 2007;264(12): Furuta Y, Ohtani F, Kawabata H, Fukuda S, Bergström T. High prevalence of varicellazoster virus reactivation in herpes simplex virus-seronegative patients with acute peripheral facial palsy. Clin Infect Dis. 2000;30(3): Hollis S, Campbell F. What is meant by intention to treat analysis? survey of published randomised controlled trials. BMJ. 1999;319(7211): Gravel J, Opatrny L, Shapiro S. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say? Clin Trials. 2007;4(4):
Viral Antibody Titer Changes in Acute and Convalescent Stage of Bell s Palsy
Journal of the K. S. C. N. Vol. 3, No. 1 Viral Antibody Titer Changes in Acute and Convalescent Stage of Bell s Palsy Sang Il Suh, M.D., Joon Soek Bae, M.D., Sung Je Kim, M.D., Tae Il Kim M.D., Ji Eun
More informationAntiviral treatment for Bell s palsy(idiopathic facial paralysis)(review)
Cochrane Database of Systematic Reviews Antiviral treatment for Bell s palsy(idiopathic facial paralysis) (Review) GagyorI,MadhokVB,DalyF,SomasundaraD,SullivanM,GammieF,SullivanF GagyorI,MadhokVB,DalyF,SomasundaraD,SullivanM,GammieF,SullivanF.
More informationAntiviral treatment for Bell s palsy(idiopathic facial paralysis)(review)
Cochrane Database of Systematic Reviews Antiviral treatment for Bell s palsy(idiopathic facial paralysis) (Review) GagyorI,MadhokVB,DalyF,SomasundaraD,SullivanM,GammieF,SullivanF GagyorI,MadhokVB,DalyF,SomasundaraD,SullivanM,GammieF,SullivanF.
More informationRESEARCH. The benefits of steroids versus steroids plus antivirals for treatment of Bell s palsy: a meta-analysis
The benefits of steroids versus steroids for treatment of Bell s palsy: a meta-analysis Eudocia C Quant, neuro-oncology fellow, 1,2 Shafali S Jeste, neurologist, 3,2 Rajeev H Muni, ophthalmologist, 4 Alison
More informationBELL PALSY OR IDIOPATHIC FAcial
CLINICAL REVIEW CLINICIAN S CORNER Combined Corticosteroid and Antiviral Treatment for Bell Palsy A Systematic Review and Meta-analysis John R. de Almeida, MD Murtadha Al Khabori, MD Gordon H. Guyatt,
More informationOriginal Article Steroid-antivirals treatment versus steroids alone for the treatment of Bell s palsy: a meta-analysis
Int J Clin Exp Med 2015;8(1):413-421 www.ijcem.com /ISSN:1940-5901/IJCEM0003349 Original Article Steroid-antivirals treatment versus steroids alone for the treatment of Bell s palsy: a meta-analysis Yabing
More informationNerve growth factor for Bell's palsy: A meta analysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 501-506, 2015 Nerve growth factor for Bell's palsy: A meta analysis YIPENG SU 1,2*, XIAOMENG DONG 1,2*, JUAN LIU 3, YAOZHI HU 1,2 and JINBO CHEN 2 1 Binzhou Medical
More informationGUIDELINE FOR THE MANAGEMENT OF IDIOPATHIC FACIAL PALSY. All children under 16 presenting to UHW or CHfW with IFP. Dr P Jeffrey Morgan ST8
GUIDELINE FOR THE MANAGEMENT OF IDIOPATHIC FACIAL PALSY Reference: IFP Version No: 1 Applicable to All children under 16 presenting to UHW or CHfW with IFP Classification of document: Area for Circulation:
More informationA Network Meta-Analysis to Compare the Efficacy of Steroid and Antiviral Medications for Facial Paralysis from Bell s Palsy
Pain Physician 2018; 21:559-569 ISSN 1533-3159 Systematic Review A Network Meta-Analysis to Compare the Efficacy of and Antiviral Medications for Facial Paralysis from Bell s Palsy Xiying Fu, MD 1, Linda
More informationAuthors' objectives To evaluate the efficacy of intravenous immunoglobulin (IVIG) for neurologic conditions.
Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review Fergusson D, Hutton B, Sharma M, Tinmouth A, Wilson K, Cameron D W, Hebert P C CRD summary This review assessed
More informationBell s palsy: a summary of current evidence and referral algorithm
Family Practice, 2014, Vol. 31, No. 6, 631 642 doi:10.1093/fampra/cmu058 Advance Access publication 10 September 2014 Bell s palsy: a summary of current evidence and referral algorithm Graeme E Glass a,
More informationCorticosteroid and antiviral therapy for Bell s palsy: A network meta-analysis
RESEARCH ARTICLE Open Access Corticosteroid and antiviral therapy for Bell s palsy: A network meta-analysis Pawin Numthavaj 1, Ammarin Thakkinstian 1*, Charungthai Dejthevaporn 2, John Attia 3 Abstract
More informationAssociation between Herpes Simplex Type 1 Virus Infection and Bell s Palsy
ARC Journal of Cancer science Volume 3, Issue 1, 2017, PP 18-22 ISSN No. (Online) 2455-6009 DOI: http://dx.doi.org/10.20431/2455-6009.0301003 www.arcjournals.org Association between Herpes Simplex Type
More informationFor citation purposes, the electronic version is the definitive version of this article:
Clinical P r a c t i c e Management of Bell s Palsy: A Report of 2 Cases Melissa Rodrigues de Araujo, DDS, MSc; Marcelo Rodrigues Azenha, DDS; Marcos Maurício Capelari, DDS; Clovis Marzola, DDS, MSc, PhD
More informationPeripheral facial paralysis in children can be caused by a
ORIGINAL STUDIES Varicella-Zoster Virus Reactivation Is an Important Cause of Acute Peripheral Facial Paralysis in Children Yasushi Furuta, MD,* Fumio Ohtani, MD,* Hiroshi Aizawa, MD,* Satoshi Fukuda,
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationEvaluation and Management of Bell's Palsy January 2002
TITLE: Evaluation and Management of Bell s Palsy SOURCE: Grand Rounds Presentation, UTMB, Dept. of Otolaryngology DATE: January 29, 2002 RESIDENT PHYSICIAN: Russell D. Briggs, MD FACULTY PHYSICIAN: Byron
More informationVol.22, ,500 mg day 7 1. NSAIDs. NSAIDs.
VZV Ramsay-Hunt Vol.22, 2015 I 2 1 65 2014 3 3 12 12 13 NSAIDs 13 14 1 2 3 2015 4 7 2015 6 22 J-STAGE 2015 9 25 567-0801 1-1-41 E-mail esenba@wakayama-med.ac.jp 17 X MRI 1 2 18 1,500 mg day 7 1 NSAIDs
More informationRamsay Hunt syndrome a case report and review of literature
From the SelectedWorks of Balasubramanian Thiagarajan January 1, 2013 Ramsay Hunt syndrome a case report and review of literature Balasubramanian Thiagarajan Available at: https://works.bepress.com/drtbalu/27/
More informationBell s Palsy. clinical practice. clinical problem. Donald H. Gilden, M.D.
clinical practice Bell s Palsy Donald H. Gilden, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented,
More informationDelayed facial nerve decompression for severe refractory cases of Bell s palsy:a 25-year experience
Berania et al. Journal of Otolaryngology - Head and Neck Surgery (2018) 47:1 DOI 10.1186/s40463-017-0250-y ORIGINAL RESEARCH ARTICLE Open Access Delayed facial nerve decompression for severe refractory
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationCritical appraisal: Systematic Review & Meta-analysis
Critical appraisal: Systematic Review & Meta-analysis Atiporn Ingsathit MD.PhD. Section for Clinical Epidemiology and biostatistics Faculty of Medicine Ramathibodi Hospital Mahidol University What is a
More informationCochrane Breast Cancer Group
Cochrane Breast Cancer Group Version and date: V3.2, September 2013 Intervention Cochrane Protocol checklist for authors This checklist is designed to help you (the authors) complete your Cochrane Protocol.
More informationA prospective randomised controlled study on efficacies of acupuncture and steroid in treatment of idiopathic peripheral facial paralysis
1 Department of ENT, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, PR China; 2 Department of Physiotherapy, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, PR China; 3 Pamela Youde
More informationEarly Treatment with Prednisolone or Acyclovir in Bell s Palsy
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Early Treatment with Prednisolone or Acyclovir in Bell s Palsy Frank M. Sullivan, Ph.D., Iain R.C. Swan, M.D., Peter T. Donnan, Ph.D.,
More informationSystematic review with multiple treatment comparison metaanalysis. on interventions for hepatic encephalopathy
Systematic review with multiple treatment comparison metaanalysis on interventions for hepatic encephalopathy Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated with severe
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationInternational Journal of Research and Review E-ISSN: ; P-ISSN:
International Journal of Research and Review www.ijrrjournal.com E-ISSN: 2349-9788; P-ISSN: 2454-2237 Original Research Article Effectiveness of Facial Nerve Stimulation with Kabat Technique in Bell s
More informationSystematic Reviews and Meta- Analysis in Kidney Transplantation
Systematic Reviews and Meta- Analysis in Kidney Transplantation Greg Knoll MD MSc Associate Professor of Medicine Medical Director, Kidney Transplantation University of Ottawa and The Ottawa Hospital KRESCENT
More informationEconomic evaluation of early administration of prednisolone. and/or aciclovir for the treatment of Bell s palsy
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Family Practice following peer review. The definitive publisherauthenticated version, Family Practice 2009;26(2):137-44is
More informationFacial Nerve Palsy. James M. Gilchrist
Facial Nerve Palsy James M. Gilchrist 7 Abstract Facial neuropathy is the most common cranial neuropathy, due to its extensive course and multiple sites of potential injury. The causes of facial neuropathy
More informationJournal of Pediatric Sciences
Journal of Pediatric Sciences Bells Palsy in Children A review Arif Khan, Nahin Hussain, Jayaprakash Gosalakkal Journal of Pediatric Sciences 2011;3(2):e77 How to cite this article: Khan A, Hussain N,
More informationBell s palsy is an idiopathic peripheral nerve (cranial. Cutaneous Sensibility Changes in Bell s Palsy Patients
Original Research General Otolaryngology Cutaneous Sensibility Changes in Bell s Palsy Patients Carlos Andrés Cárdenas Palacio, MS 1, and Francisco Alejandro Múnera Galarza, PhD, MS 2 Otolaryngology Head
More informationComparison of Facial Nerve Paralysis in Adults and Children
Yonsei Med J 49(5):725-734, 2008 DOI 10.3349/ymj.2008.49.5.725 Comparison of Facial Nerve Paralysis in Adults and Children Chang Il Cha, Chang Kee Hong, Moon Suh Park, and Seung Geun Yeo Department of
More informationOriginal Article. Bangladesh Med J Jan; 46 (1)
Original Article Effect of Infrared Radiation (IRR) on Patients with Bell s Palsy *Banu HB 1, Rahman S 2, Hossain S 3,Nessa j 4, Khan EH 5,Mahmood K 6, Rahman DML 7,Ahmed M 8 Abstract This prospective
More informationHyperbaric oxygen therapy Villanueva E, Johnston R, Clavisi O, Burrows E, Bernath V, Rajendran M, Wasiak J, Fennessy P, Anderson J, Harris A, Yong K
Hyperbaric oxygen therapy Villanueva E, Johnston R, Clavisi O, Burrows E, Bernath V, Rajendran M, Wasiak J, Fennessy P, Anderson J, Harris A, Yong K Authors' objectives To assess the effectiveness of hyperbaric
More informationOutcomes assessed in the review
The effectiveness of mechanical compression devices in attaining hemostasis after removal of a femoral sheath following femoral artery cannulation for cardiac interventional procedures Jones T Authors'
More informationEfficacy of acupuncture and moxibustion in treating Bell s palsy : a multicenter randomized controlled trial in China
1502 Efficacy of acupuncture and moxibustion in treating Bell s palsy : a multicenter randomized controlled trial in China LI Ying, LIANG Fan2rong, YU Shu2guang, LI Chang2du, HU Ling2xiang ZHOU Dong, YUAN
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationHerpes zoster. Diagnosis, Complications, Treatment, Prevention 서울대학교병원 FM R2 임하연
Herpes zoster Diagnosis, Complications, Treatment, Prevention 2018.04.14 서울대학교병원 FM R2 임하연 1 2 Overview reactivation of lat ent VZV along sensory nerve VZV(varicella-zoster virus) Human herpes virus-3
More informationCochrane Pregnancy and Childbirth Group Methodological Guidelines
Cochrane Pregnancy and Childbirth Group Methodological Guidelines [Prepared by Simon Gates: July 2009, updated July 2012] These guidelines are intended to aid quality and consistency across the reviews
More informationASSESSMENT AND TREATMENT OF FACIAL PALSY. Michael J. LaRouere, M.D. Michigan Ear Institute Farmington Hills, Michigan
ASSESSMENT AND TREATMENT OF FACIAL PALSY Michael J. LaRouere, M.D. Michigan Ear Institute Farmington Hills, Michigan FACIAL PARALYSIS - ETIOLOGY Bells Palsy Ramsay Hunt Syndrome Infection (Acute/Chronic)
More informationThe most common symptom of Bell's palsy is not being able to move the muscles on one side of your face.
Patient information from the BMJ Group Bell's palsy What is it? What are the symptoms? How is it diagnosed? How common is it? What treatments work? What will happen? Questions to ask Bell's palsy If you
More informationTranstympanic Micropressure Applications as a Treatment of Meniere s Disease
Transtympanic Micropressure Applications as a Treatment of Meniere s Disease Policy Number: 1.01.23 Last Review: 8/2017 Origination: 2/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationWorkshop: Cochrane Rehabilitation 05th May Trusted evidence. Informed decisions. Better health.
Workshop: Cochrane Rehabilitation 05th May 2018 Trusted evidence. Informed decisions. Better health. Disclosure I have no conflicts of interest with anything in this presentation How to read a systematic
More informationReceived 5 December 2003; accepted 21 January 2004
Journal of Antimicrobial Chemotherapy (2004) 53, 703 707 DOI: 10.1093/jac/dkh154 Advance Access publication 24 March 2004 Clinical significance of antiviral therapy for episodic treatment of herpes labialis:
More informationMarch 1, 2006 Table of Contents. What is the best treatment for patients with an outbreak of herpes zoster?
March 1, 2006 Table of Contents FPIN's Clinical Inquiries Treatment of Herpes Zoster Clinical Question What is the best treatment for patients with an outbreak of herpes zoster? Evidence-Based Answer Resolution
More information5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA
5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA Background RCTs investigating the efficacy of aminosalicylates for
More informationStudy selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were eligible for inclusion in the review.
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses Stokman M A, Spijkervet F K, Boezen H M, Schouten J P, Roodenburg J L, de Vries
More informationMethylprednisolone, Valacyclovir, or the Combination for Vestibular Neuritis
The new england journal of medicine original article Methylprednisolone, Valacyclovir, or the Combination for Vestibular Neuritis Michael Strupp, M.D., Vera Carina Zingler, M.D., Viktor Arbusow, M.D.,
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationCorticosteroids for preventing postherpetic neuralgia (Review)
Corticosteroids for preventing postherpetic neuralgia (Review) Chen N, Yang M, He L, Zhang D, Zhou M, Zhu C This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationDatabase of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown
More informationClinical Policy Bulletin: Bell's Palsy
Go Clinical Policy Bulletin: Bell's Palsy Number: 0745 Policy *Pleasesee amendment forpennsylvaniamedicaidattheendofthiscpb. I. Aetna considers blink reflex testing medically necessary for the diagnosis
More informationWestern Blot Analysis for Diagnosis of Lyme Disease in Acute Facial Palsy
The Laryngoscope Lippincott Williams & Wilkins, Inc., Philadelphia 2001 The American Laryngological, Rhinological and Otological Society, Inc. Western Blot Analysis for Diagnosis of Lyme Disease in Acute
More informationVaricella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus
Varicella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus Helena M. Tabery Varicella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus In Vivo Morphology in the Human Cornea
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews The effect of probiotics on functional constipation: a systematic review of randomised controlled trials EIRINI DIMIDI, STEPHANOS CHRISTODOULIDES,
More informationFacial Paralysis: Objectives: Discuss the anatomy of the facial nerve. Look at common patterns of facial nerve palsy
Facial Paralysis: Objectives: Discuss the anatomy of the facial nerve Look at common patterns of facial nerve palsy Discuss imaging appearance of lesions that lead to facial paralysis. Lindell R. Gentry,
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationORIGINAL ARTICLE. Is Bell s palsy a component of polyneuropathy?
ORIGINAL ARTICLE Is Bell s palsy a component of polyneuropathy? Tu ba Tunç MD, Erkan Tarhan MD,, Haldun O uz MD, Mustafa As m Þafak MD, Gülnihal Kutlu MD, Levent E. nan MD From Ministry of Health, Ankara
More informationHerpetic Eye Disease Jason Duncan, OD, FAAO Diplomate, American Board of Optometry Associate Professor, Southern College of Optometry
Herpetic Eye Disease Jason Duncan, OD, FAAO Diplomate, American Board of Optometry Associate Professor, Southern College of Optometry I have what?! How to break the news Meet the Herpes Quick virology
More informationBMJ Open. Prognostication of recovery time after acute peripheral facial palsy
Prognostication of recovery time after acute peripheral facial palsy Journal: Manuscript ID: bmjopen-0-000 Article Type: Research Date Submitted by the Author: 0-Apr-0 Complete List of Authors: Volk, Gerd;
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Review title and timescale 1 Review title Give the working title of the review. This must be in English. Ideally it should state succinctly
More informationReview. Key words : asthma, benralizumab, interleukin-5, mepolizumab, reslizumab. Introduction
Showa Univ J Med Sci 30 1, 11 25, March 2018 Review Comparative Efficacy and Safety of Anti-Interleukin-5 Therapies and Placebo in Patients with Uncontrolled Eosinophilic Asthma : A Systematic Review and
More informationAlectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis
Showa Univ J Med Sci 30 2, 309 315, June 2018 Original Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis Ryo MANABE 1, Koichi ANDO
More informationVia Transmastoid Approach. Mitul Chaitan Bhatt. Maharashtra University Miraj India
ISSN: 2250-0359 Volume 6 Issue 1 2016 Evaluation Of Patients Of Traumatic Facial Palsy Treated By Facial Nerve Decompression Via Transmastoid Approach Mitul Chaitan Bhatt Maharashtra University Miraj India
More informationThe angiotensin-converting enzyme (ACE) I/D polymorphism in Parkinson s disease
4432JRA0010.1177/1470320313494432Journal of the Renin-Angiotensin-Aldosterone SystemSu et al Original Article The angiotensin-converting enzyme (ACE) I/D polymorphism in Parkinson s disease Journal of
More information2. The effectiveness of combined androgen blockade versus monotherapy.
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Blue Cross and Blue Shield Association, Aronson N, Seidenfeld J Authors' objectives
More informationNeuRA Sleep disturbance April 2016
Introduction People with schizophrenia may show disturbances in the amount, or the quality of sleep they generally receive. Typically sleep follows a characteristic pattern of four stages, where stage
More informationIt has been estimated that 90% of individuals
Famciclovir for Cutaneous Herpesvirus Infections: An Update and Review of New Single-Day Dosing Indications Manju Chacko, MD; Jeffrey M. Weinberg, MD Infections with herpes simplex virus (HSV) types 1
More informationAllergen immunotherapy for the treatment of allergic rhinitis and/or asthma
ril 2014 Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma FINAL COMPREHENSIVE RESEARCH PLAN June 2015 Study Team: Systematic Review Unit FINAL COMPREHENSIVE RESEARCH PLAN: Systematic
More informationEfficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis
1 Cardiology Department, Maria Vittoria Hospital, Torino, Italy 2 Ospedali Riuniti, Bergamo, Italy 3 Cardiac Surgery, Ospedale Mauriziano, Torino, Italy 4 Sheba Medical Center, Tel Hashomer and Sackler
More informationSubunit adjuvanted zoster vaccine: why the fuss?
Subunit adjuvanted zoster vaccine: why the fuss? Soren Gantt, MD PhD MPH Pediatric Infectious Diseases Vaccine Evaluation Center BC Children s Hospital University of British Columbia Disclosures Research
More informationThe chemical name of acyclovir, USP is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6Hpurin-6-one; it has the following structural formula:
Acyclovir Ointment, USP 5% DESCRIPTION Acyclovir, USP, is a synthetic nucleoside analogue active against herpes viruses. Acyclovir ointment, USP 5% is a formulation for topical administration. Each gram
More informationEfficacy of postoperative epidural analgesia Block B M, Liu S S, Rowlingson A J, Cowan A R, Cowan J A, Wu C L
Efficacy of postoperative epidural analgesia Block B M, Liu S S, Rowlingson A J, Cowan A R, Cowan J A, Wu C L CRD summary This review evaluated the efficacy of post-operative epidural analgesia. The authors
More informationSafinamide (Addendum to Commission A15-18) 1
IQWiG Reports Commission No. A15-41 Safinamide (Addendum to Commission A15-18) 1 Addendum Commission:A15-41 Version: 1.1 Status: 29 October 2015 1 Translation of addendum A15-41 Safinamid (Addendum zum
More informationOut of date SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence)
Membranous nephropathy role of cyclosporine therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. The use of cyclosporine therapy alone to prevent progressive
More informationUSDA Nutrition Evidence Library: Systematic Review Methodology
USDA Nutrition Evidence Library: Systematic Review Methodology Julie E. Obbagy, PhD, RD USDA Center for Nutrition Policy & Promotion Meeting #2 October 17, 2016 The National Academies of Sciences, Engineering,
More informationAssessing risk of bias
Assessing risk of bias Norwegian Research School for Global Health Atle Fretheim Research Director, Norwegian Institute of Public Health Professor II, Uiniversity of Oslo Goal for the day We all have an
More informationSudden sensorineural hearing loss (SSNHL) is defined
Transtympanic steroids for treatment of sudden hearing loss GERARD J. GIANOLI, MD, FACS, and JOHN C. LI, MD, FACS, Baton Rouge, Louisiana, and Jupiter, Florida OBJECTIVES: To determine whether transtympanic
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews A systematic review of behaviour change interventions targeting physical activity, exercise and HbA1c in adults with type 2 diabetes Leah
More informationDose: Metoclopramide -0.1 mg/kg (max 10 mg) IV, over 15 minutes
Metoclopramide for Refractory Migraine in the ED Specific Care Question : In the pediatric patient diagnosed with refractory migraine, is metoclopramide an effective treatment? Question Originator: Migraine
More informationData extraction. Specific interventions included in the review Dressings and topical agents in relation to wound healing.
Systematic reviews of wound care management: (2) dressings and topical agents used in the healing of chronic wounds Bradley M, Cullum N, Nelson E A, Petticrew M, Sheldon T, Torgerson D Authors' objectives
More informationPage: 1 of 6. Transtympanic Micropressure Applications as a Treatment of Meniere's Disease
Page: 1 of 6 Last Review Status/Date: December 2013 as a Treatment of Meniere's Disease Description Transtympanic micropressure treatment for Meniere s disease involves use of a hand-held air pressure
More informationTranstympanic Micropressure Applications as a Treatment of Meniere s Disease
Transtympanic Micropressure Applications as a Treatment of Meniere s Disease Policy Number: 1.01.23 Last Review: 8/2014 Origination: 2/2006 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas
More informationRamsay Hunt syndrome. Younghoon Jeon, Heryim Lee INTRODUCTION. Review Article
Review Article pissn 2383-9309 eissn 2383-9317 J Dent Anesth Pain Med 2018;18(6):333-337 https://doi.org/10.17245/jdapm.2018.18.6.333 Department of Anesthesiology and Pain Medicine, School of Dentistry,
More informationEarly View Article: Online published version of an accepted article before publication in the final form.
: Online published version of an accepted article before publication in the final form. Journal Name: International Journal of Case Reports and Images (IJCRI) Type of Article: Case Report Title: Post Herpetic
More informationResearch Article Clinical Features of Bell s Palsy in Children and Outcomes of Physical Therapy: A Retrospective Study
ISRN Rehabilitation Volume 2013, Article ID 501034, 6 pages http://dx.doi.org/10.1155/2013/501034 Research Article Clinical Features of Bell s Palsy in Children and Outcomes of Physical Therapy: A Retrospective
More informationAcyclovir for ear infections
Acyclovir for ear infections The Borg System is 100 % Acyclovir for ear infections User feedback about Acyclovir side effects covering chicken pox, fatigue, shingles, hair loss, HSV2, dosage, anemia, ear
More information1. PICO question. Interventions Reference standard or comparators Outcomes. Study design Other
Title: Strategies for optimizing HIV monitoring among adults, children and pregnant women living with HIV receiving antiretroviral therapy: a systematic review Contents 1. PICO question... 1 2. Search
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sullivan FM, Swan IRC, Donnan PT, et al. Early treatment with
More informationThe diagnosis of Chronic Pancreatitis
The diagnosis of Chronic Pancreatitis 1. Background The diagnosis of chronic pancreatitis (CP) is challenging. Chronic pancreatitis is a disease process consisting of: fibrosis of the pancreas (potentially
More informationPICC or peripheral intravenous catheter?
PICC or peripheral intravenous catheter? B.S. Niël-Weise 1, P.J. van den Broek 2 1 Dutch Infection Prevention Working Party, Leiden, The Netherlands 2 Department of Infectious Diseases, Leiden University
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationObstructive sleep apnea (OSA) is the periodic reduction
Obstructive Sleep Apnea and Oxygen Therapy: A Systematic Review of the Literature and Meta-Analysis 1 Department of Anesthesiology, Toronto Western Hospital, University Health Network, University of Toronto,
More informationWhat A Headache! Theresa Biesiada March 8, 2012
What A Headache! Theresa Biesiada March 8, 2012 Objectives Describe the EM relevance of headaches and migraines Discuss the rationale for steroid therapy Review the evidence Conclusions My inspiration
More informationThe QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews
The QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews David Moher 1, Alessandro Liberati 2, Douglas G Altman 3, Jennifer Tetzlaff 1 for the QUOROM Group
More informationPROTOCOL. Francesco Brigo, Luigi Giuseppe Bongiovanni
COMMON REFERENCE-BASED INDIRECT COMPARISON META-ANALYSIS OF INTRAVENOUS VALPROATE VERSUS INTRAVENOUS PHENOBARBITONE IN GENERALIZED CONVULSIVE STATUS EPILEPTICUS PROTOCOL Francesco Brigo, Luigi Giuseppe
More information